Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
D002170:Canada; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004346:Drug Information Services; D005194:Family Practice; D017408:Guidelines as Topic; D006801:Humans; D033181:Information Dissemination; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib